AIMA expertise stems from the cyclotron laboratory of the Centre Antoine Lacassagne (CAL), that designed and built MEDICYC, the first hospital-based cyclotron facility in France for protontherapy. For more than 33 years, MEDICYC has successfully treated more than 9000 patients. 

​

From 2009 to 2012, AIMA Developpement developped a new superconducting synchrocyclotron (S2C2™) for high energy (230 MeV) protontherapy of deep seated tumors. This conceptual design was adopted by the IBA Company, a world leading manufacturer of medical accelerators for protontherapy.

The prototype of the S2C2™ is installed in the Institut Méditerranéen de Protonthérapie (IMPT) of the Centre Antoine Lacassagne. Both MEDICYC and the S2C2™ are providing a world leading facility for the development of protontherapy. A dedicated R&D beam line has also been designed by AIMA.